{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-125866","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2025-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.638226+00:00","generated_at":"2026-05-20T14:49:58.999103+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"COO Brett Kaplan departs Climb Bio; CEO Aoife Brennan named interim PFO","bullets":["Brett Kaplan, COO and principal financial officer, separated mutually on May 23, 2025.","Kaplan receives severance: 3 months base salary ($128,749.99) plus COBRA for 3 months.","CEO Aoife Brennan appointed interim principal financial officer, effective May 24, 2025, retaining CEO role.","No changes to Brennan's compensation or arrangements in connection with this appointment.","Kaplan reaffirms confidentiality, non-compete (amended to exclude CD19/APRIL drugs), and non-solicitation obligations."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-125866","json":"https://secwatch.observer/filing/0001193125-25-125866.json","markdown":"https://secwatch.observer/filing/0001193125-25-125866.md","text":"https://secwatch.observer/filing/0001193125-25-125866.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000119312525125866/0001193125-25-125866-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000119312525125866/d854335d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T14:49:58.999103+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5152ef3cc3","claim":"Brett Kaplan departed as Chief Operating Officer and principal financial officer at Climb Bio, Inc..","evidence_excerpt":"On May 23, 2025, Climb Bio, Inc. (the “Company”) and Brett Kaplan, M.D., its Chief Operating Officer and principal financial officer, mutually agreed that Dr. Kaplan would separate from the Company, effective May 23, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768446/000119312525125866/0001193125-25-125866-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"Chief Operating Officer and principal financial officer"}],"fact_type":"executive_change"},{"claim_id":"db2fc51311","claim":"Aoife Brennan was appointed as interim principal financial officer at Climb Bio, Inc..","evidence_excerpt":"On the Separation Date, the Board of Directors of the Company appointed Aoife Brennan as the Company’s interim principal financial officer, effective as of May 24, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768446/000119312525125866/0001193125-25-125866-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim principal financial officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}